Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01670032 · ClinicalTrials.gov registry record · Phase 2
Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 328
- Enrollment target
NCT01670032: Completed Phase 2 study, sponsored by NovaBay Pharmaceuticals.
NCT01670032 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 328 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01670032, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 328 participants
- Enrollment target
Study Summary
This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel applied TID; Vehicle Topical Gel applied BID;Vehicle Topical Gel applied TID. All treatments will be administered for 7 days. Disease activity for the Target Lesion will be evaluated using the Skin Infection Rating Scale (SIRS) Score.
Primary Outcome
Clinical Success is defined by the SIRS score of the Target Lesion
Interventions
- DRUG Experimental: CD07223 1.5 % Topical Gel BID
- DRUG Experimental: CD07223 1.5% Topical Gel TID
- DRUG Placebo Comparator: CD07223 vehicle gel BID
- DRUG Placebo Comparator: CD07223 vehicle gel TID
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 328 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
What the finished NCT01670032 record still lists
NCT01670032 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 4 interventions - of which Experimental: CD07223 1.5 % Topical Gel BID is the first listed.
NCT01670032 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01670032 about?
NCT01670032 is a clinical study titled "Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo". This study will be a multicenter, randomized, vehicle controlled, parallel, group, double blind study. Eligible subjects with a clinical diagnosis of impetigo will be randomized to one of four treatment groups: 1.5% CD07223 Topical Gel applied BID; 1.5% CD07223 Topical Gel applied TID; Vehicle Topic...
What is the current status of trial NCT01670032?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 328 participants. The study started on 2012-08. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01670032?
The interventions under investigation include: Experimental: CD07223 1.5 % Topical Gel BID (DRUG), Experimental: CD07223 1.5% Topical Gel TID (DRUG), Placebo Comparator: CD07223 vehicle gel BID (DRUG), Placebo Comparator: CD07223 vehicle gel TID (DRUG).
Who is sponsoring clinical trial NCT01670032?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01670032's enrollment target sits among peer trials
328 146th of 2000 higher than 1,855 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05156983 · 328 participants · Phase 3
A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery
- NCT05380401 · 328 participants · NA
Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants
- NCT05548413 · 328 participants · NA
Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies
- NCT06393725 · 328 participants · NA
Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia